Gyn Endometrial Stage
Pathologic Staging
Majority of patients are Stage I or II at diagnosis.
Prior to 1988 – disease was clinically staged. System now used only for inoperable patients as disease is now surgically staged.
Surgical staging allows determination and assessment of defined prognostic factors.
1988 FIGO Surgical Staging
FIGO Stage | Description | Survival |
I | Limited to corpus | |
IA | Limited to endometrium | 91% |
IB | < ½ myometrial invasion | 88% |
IC | > ½ myometrial invasion | 81% |
II | Extension to cervix | |
IIA | Endocervical gland involvement | 77% |
IIB | Cervical stroma invasion | 67% |
III | Beyond uterus | |
IIIA | Serosal / adnexal involvement or + peritoneal cytology | 60% |
IIIB | Vaginal involvement | 41% |
IIIC | + pelvic or PA nodes | 32% |
IV | Beyond pelvis or bladder or rectum | |
IVA | Bladder / rectal mucosa involvement | 5% |
IVB | Distant metastases | < 5% |
Clinical Staging
0 | Carcinoma in situ |
I | Limited to corpus |
IA | < 8 cm |
IB | ≥ 8 cm |
IG1 | Highly differentiated adenocarcinoma |
IG2 | Partially Solid Areas |
IG2 | Predominantly Solid Areas |
II | Extension to cervix |
III | Beyond uterus but not true pelvis (not involving bladder or rectum) |
IV | Bladder / rectal mucosa involvement or outside true pelvis |
page revision: 2, last edited: 24 Mar 2008 02:41